Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial.
Hirota M, Shimosegawa T, Kitamura K, Takeda K, Takeyama Y, Mayumi T, Ito T, Takenaka M, Iwasaki E, Sawano H, Ishida E, Miura S, Masamune A, Nakai Y, Mitoro A, Maguchi H, Kimura K, Sanuki T, Ito T, Haradome H, Kozaka K, Gabata T, Kataoka K, Hirota M, Isaji S, Nakamura R, Yamagiwa K, Kayaba C, Ikeda K.
Hirota M, et al. Among authors: sanuki t.
J Gastroenterol. 2020 Mar;55(3):342-352. doi: 10.1007/s00535-019-01644-z. Epub 2019 Nov 22.
J Gastroenterol. 2020.
PMID: 31758329
Free PMC article.
Clinical Trial.